CD36 Promotes Vasculogenic Mimicry in Melanoma by Mediating Adhesion to the Extracellular Matrix

Carmela Martini
University of South Australia

Mark DeNichilo
University of South Australia

Danielle P. King
University of South Australia

Michaelia P. Cockshell
University of South Australia

Brenton Ebert
University of South Australia

Brian Dale
University of South Australia

Lisa M. Ebert
SA Pathology

Anthony Woods
University of South Australia

Claudine S Bonder (✉ claudine.bonder@unisa.edu.au)
University of South Australia  https://orcid.org/0000-0001-9875-967X

Research article

Keywords: CD36, vasculogenic mimicry, melanoma, tumor microenvironment, thrombospondin, laminin, integrin

DOI: https://doi.org/10.21203/rs.3.rs-531244/v1

License: ☕️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: The formation of blood vessels within solid tumors directly contributes to cancer growth and metastasis. Until recently, tumor vasculature was thought to occur exclusively via endothelial cell (EC) lined structures (i.e. angiogenesis), but a second source of tumor vasculature arises from the cancer cells themselves, a process known as vasculogenic mimicry (VM). While it is generally understood that the function of VM vessels is the same as that of EC-lined vessels (i.e. to supply oxygen and nutrients to the proliferating cancer cells), the molecular mechanisms underpinning VM are yet to be fully elucidated.

Methods: Human VM-competent melanoma cell lines were examined for their VM potential using the in vitro angiogenesis assays (Matrigel), together with inhibition studies using small interfering RNA and blocking monoclonal antibodies. Invasion assays and adhesion assays were used to examine cancer cell function.

Results: Herein we demonstrate that CD36, a cell surface glycoprotein known to promote angiogenesis by ECs, also supports VM formation by human melanoma cancer cells. In silico analysis of CD36 expression within the melanoma cohort of The Cancer Genome Atlas suggests that melanoma patients with high expression of CD36 have a poorer clinical outcome. Using in vitro ‘angiogenesis’ assays and CD36-knockdown approaches, we reveal that CD36 supports VM formation by human melanoma cells as well as adhesion to, and invasion through, a cancer derived extracellular matrix substrate. Interestingly, thrombospondin-1 (TSP-1), a ligand for CD36 on ECs that inhibits angiogenesis, has no effect on VM formation. Further investigation revealed a role for laminin, but not collagen or fibronectin, as ligands for CD36 expressing melanoma cells.

Conclusions: Taken together, this study suggests that CD36 is a novel regulator of VM by melanoma cancer cells that is facilitated, at least in part, via integrin-a3 and laminin. Unlike angiogenesis, VM is not perturbed by the presence of TSP-1, thus providing new information on differences between these two processes of tumor vascularization which may be exploited to combat cancer progression.

Background

Angiogenesis is the most common mechanism by which tumors become vascularized and metastasize. However, the growing mass can also utilise other processes to form vascular networks, such as vasculogenic mimicry (VM). First identified in aggressive uveal melanoma cells, VM has since been seen in several aggressive malignancies such as glioblastoma[1–3], colorectal cancer[4, 5], breast cancer[6, 7], ovarian cancer[8, 9], pancreatic cancer[10] and prostate cancer[11]. VM occurs when highly aggressive malignant cells undergo cellular phenotypic changes to resemble endothelial cells (ECs) which form the inner lining of all vasculature. While these malignant cells display EC markers, i.e. vascular endothelial (VE)-cadherin, ephrin receptor A2 (EphA2) and E-selectin, and like ECs can secrete many basement membrane relevant proteins, they do however have little to no expression of EC-specific proteins such as CD31 (PECAM-1) and TIE-2[12, 13]. Histological staining with the periodic acid-Schiff stain (PAS,
recognizing basement membrane proteins) used in conjunction with an antibody to CD31 being the universally accepted protocol to distinguish VM structures as PAS-positive/CD31-negative from the EC-lined PAS-positive/CD31-positive vasculature[14–16].

The aggressive nature of VM is supported by evidence of these structures anastomosing with traditional EC-lined tumor vasculature[17]; and in doing so, it further enables the solid tumor mass to gain access to oxygen and nutrients for growth[18]. VM content in tumors is undeniably an indicator of poor patient prognosis, including metastatic disease and overall survival[16, 19]. Meta-analyses of different cancer types show that patients with tumors that are high in VM content have a significantly lower 5-year overall survival rate when compared to those with little/no VM content[20]. Despite the similarities between angiogenesis and VM, current anti-angiogenic approaches fail to target VM vascular structures and indeed the use of antiangiogenic therapy (bevacizumab) has been shown to increase VM in ovarian and breast cancer[21, 22]. Anti-VM therapies have had limited success, with currently only one drug, CVM-1118 (NCT03582618), in Phase 2 open label clinical trial[23, 24]. Hence, understanding the mechanisms involved in VM formation is clearly clinically important.

CD36 is an 88kDa cell surface glycoprotein well documented as a scavenger receptor on many cell types, including platelets, phagocytic cells, adipocytes, erythrocytes, specialized epithelia, myocytes and microvascular endothelium (reviewed in [25]). The functional diversity of CD36 is underpinned by its binding to distinct ligands including long chain fatty acids, phospholipids, oxidized low-density lipoprotein (oxLDL), amyloid proteins, advanced glycation end products and thrombospondin (TSP)[25]. In tumor tissues, CD36 is expressed by cancer cells, ECs, stromal cells and immune cells[26] with numerous studies supporting the notion that CD36 participates in the progression of cancer[27–29]. More specifically, retrospective analyses suggest that elevated levels of CD36 correlate with poor prognosis in patients with glioma, cervical cancer, ovarian cancer, lung cancer, squamous-cell carcinoma, bladder cancer, and luminal A breast cancer[27–30]. Consistent with this, overexpression studies have shown CD36 to increase the migration and invasion of cervical cancer cells in vitro, and its knockdown inhibited their metastatic potential[30]. Pascual and colleagues further demonstrated that short hairpin RNA-mediated depletion of CD36 significantly reduced metastases in models of melanoma (501mel) and breast cancer (MCF-7) in vivo[29]. Hypoxia is a well-known initiator of tumor vascularization and hypoxia has also been documented to elevate CD36 expression on microvascular ECs (MVECs)[31]. Taken together, these findings begin to reveal an important inter-relationship between cancer cells, tumor ECs and CD36. Interestingly, the CD36 ligand TSP-1 has been identified as a potent inhibitor of angiogenesis as it renders ECs non-responsive to pro-angiogenic stimuli such as vascular endothelial growth factor (VEGF) via changes in intracellular signaling pathways[32, 33] and its promotion of apoptosis[34]. Elevated levels of TSP-1 have indicated some suppressive control of tumor growth and cancer metastasis[35], likely via inhibition of tumor vasculature.

On the whole, the expression of CD36 has poor implications in cancer, and while CD36 has gained significant attention in recent years, its role in tumor vasculature and cancer progression is still not fully
understood. The aim of the present study is to investigate the currently unknown role of CD36 in VM by melanoma cells.

Methods

Cell culture

Human melanoma cell lines C32 and SK-MEL-28 were gifted from G McArthur (Peter MacCallum Cancer Centre, Melbourne, Vic, AUS) and cultured in RPMI 1640 (Gibco by Life Technologies, California, USA) containing 10% fetal bovine serum (FBS) (Hyclone, GE Healthcare Sciences, Utah, USA) and 1% Glutamax 1x (Gibco) and cultured under standard conditions (37°C, 5% CO₂). Human lung microvascular endothelial cells (HMVEC) were purchased from the Lonza (Basel, Switzerland) and cultured in Lonza EBM-2 basal medium to low passage number.

Flow cytometry

To determine cell surface expression of CD36, cells were labelled with anti-human CD36 antibody (FA6-152, Stem Cell Technologies, Vancouver, Canada) or isotype control (IgG₁ κ) at a concentration of 10 µg/ml in RPMI1640 media (Sigma-Aldrich, Merck, Sydney Australia) containing 10% FBS. Cells were then washed and stained with a secondary antibody, goat anti-mouse IgG H&L Dylight 650 (Clone ab96882, Abcam, Cambridge, United Kingdom) at a concentration of 5 µg/ml. Cell viability was determined via 7AAD (BD Biosciences) staining at a 1:20 dilution. Samples were processed using a BD Accuri C6 flow cytometer (BD, Becton, Dickinson and Company, New Jersey, USA) and data analyzed using FCS Express 4 Flow Research Edition (De Novo software, Los Angeles, USA).

CD36 knockdown using siRNA

CD36 targeting small interfering RNAs (siRNAs) Trilencer-27 Human siRNA duplexes at 20µM were purchased (Origene, Maryland, USA) with three CD36 targeting siRNAs (A, B and C) plus a non-targeting scrambled (SCR) siRNA used as a negative control. Transfection was performed using Lipofectamine RNAiMAX (Invitrogen by Life Technologies, California, USA) as per the manufacturer’s instructions with the knockdown maximized at 5nM and validated by flow cytometry.

Vasculogenic mimicry (VM) assays

VM assays were performed on Geltrex LDEV-Free Reduced Growth Factor Basement Membrane Matrix (Life Technologies, California, USA) with 10ml coating each of a 15 well µ-Angiogenesis culture slides (Ibidi, Martinsreid, Germany) and allowed to solidify over 30 minutes at 37°C. Human melanoma cancer cells were then seeded at 2 x 10⁴ cells/well for C32 cells and 5 x 10³ cells/well for SK-MEL-28 cells and after 6 hours incubation at 37°C, images of each well were obtained using the EVOS XL Core Imaging System (Thermo Fisher Scientific) with brightness of the images adjusted equally across groups to enhance image contrast for ease of readers. VM structures were defined as multi-cellular arrangements forming vessel-like structures from one branch point to another[16] and VM in each well was counted in
blinded manner. A minimum of three independent experiments were performed. Similar experiments included cells without or with CD36-targeting siRNA knockdown or those pre-treated with TSP-1 (150 or 1500ng/ml), an anti-CD36 blocking antibody (10 µg/ml, FA6-152) or an isotype control (IgG₁) for 30 minutes at 4°C prior to seeding.

**Angiogenesis assays**

Human lung microvascular endothelial cells (HMVEC) were serum starved overnight in EBM-2 basal medium (Lonza, Basel, Switzerland) at 37°C prior to seeding onto Geltrex at a concentration of 2 x 10⁴ cells/well within a 15 well μ-Angiogenesis slide with or without the addition of TSP-1 (1500 ng/ml) in EBM-2 basal medium containing EGM-2 MV SingleQuot Kit supplements and growth factors (Lonza, Basel, Switzerland). After 6 hours, images of the angiogenesis formation were obtained using the EVOS XL Cell Imaging System. Angiogenesis formation was determined by blindly counting the vessel-like structures formed within each well with the use of ImageJ software.

**MTS survival assay**

HMVEC were seeded into 96-well flat bottom plates at a concentration of 2 x 10⁴ cells/well in EBM-2 basal medium containing EGM-2 MV SingleQuot Kit supplements and growth factors. Cells were incubated at 37°C for 5 hours, washed in 1x PBS, serum starved in EBM-2 basal medium overnight at 37°C and then treated without or with TSP-1 (1500 ng/ml) for 6 hours and 24 hours at 37°C. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; Life Technologies, California, USA) was then added to each well at a concentration of 0.5 mg/ml for 2 hours at 37°C. Viable cell density was determined by measuring absorbance at 490nm on the Epoch microplate spectrophotometer (Biotek, USA).

**Adhesion assays**

C32 melanoma cells (1.5 x 10⁴ cells) were seeded into wells of a flat bottom 96-well plate preloaded overnight at 4°C with 10–50 µg/ml collagen I (Becton, Dickinson and Company, New Jersey, USA), collagen IV (Sigma-Aldrich, Missouri, United States), laminin (Roche, Basel, Switzerland), fibronectin (Roche, Basel, Switzerland) or Geltrex. Cells that had undergone a 72-hour CD36-targeting siRNA knockdown were harvested and resuspended in 1 mg/ml of bovine serum albumin (BSA) (Sigma Aldrich, Missouri, USA) in RPMI 1640 and seeded into the extracellular matrix (ECM) component containing wells and incubated at 37°C for 90 minutes. Rose Bengal (Sigma Aldrich, Missouri, USA) diluted in warm 1x PBS to a concentration of 0.05%, was then added to the cells for 10 minutes at RT prior to several washes with PBS. A 1:1 solution of methanol and PBS was then added to the cells for 10 minutes prior to the absorbance reading via spectrophotometry at 562nm FLUOstar Omega plate reader (BMG LABTECH GmbH, Offenberg Germany).

Functional blocking studies using the mouse anti-integrin-α₃ mAb (Clone P1B5; Sigma Aldrich, Missouri, USA) were performed by pre-incubating C32 melanoma cells at 37°C with anti-integrin-α₃ mAb at
50µg/mL for 30 minutes prior to cell attachment to wells coated with human laminin at 50 µg/ml as described above. Images of each well were obtained using the EVOS XL Core Imaging System.

**Inverse invasion assays**

Adapted from Hennigan *et al.*[36], 100 µl of growth factor-reduced Matrigel diluted 1:1 in cold PBS was added into an 8.0µm pore sized Transwell (Corning Inc., NY, USA) and allowed to set. Transwells were then inverted and 2x10^5 C32 cells per ml (without or with CD36 knockdown via siRNA) were seeded onto the underside of the membrane. Four hours later, the unbound cells were rinsed and Transwells immersed right-way up in serum-free HUVEC media without or with 10% FBS was added to the upper chamber as chemoattractant, and cells allowed to migrate upward into the Matrigel for 48 hours. Transwells were paraformaldehyde fixed, RNase-treated (100 µg/ml, Thermo Fisher) and stained with 0.05 mg/ml of propidium iodide (Thermo Fisher); all steps were carried out for 30 minutes with two PBS washes between each. Transwells were imaged at fixed intervals (10 µm) starting at the membrane and in a direction towards the chemoattractant using z-stack setting of Zeiss LSM 700 confocal microscope with a 20x objective (Carl Zeiss AG, Oberkochen, Germany). Cells from 3 fields of view per slice were quantified using ImageJ software, through threshold adjustment and counting particles (cells), this was then averaged.

**Bioinformatics analysis of publicly available datasets**

To analyze TCGA data, RNA sequencing (RNA-seqV2) and clinical (Biotab) data were downloaded from the Data Portal at [http://cancergenome.nih.gov/](http://cancergenome.nih.gov/). Data were analyzed in Bioconductor, using the edgeR package to perform differential gene expression analysis.

**Statistical analysis**

Statistical analyses and significance were calculated by Mann Whitney U test or one-way ANOVA to determine statistical significance using GraphPad PRISM software (San Diego, CA, USA). In all comparisons, *p* < 0.05 was considered statistically significant.

**Results**

**High CD36 gene expression suggests poor clinical outcome for patients with melanoma**

Data obtained from The Cancer Genome Atlas (TCGA) was used to determine the significance of *CD36* gene expression in the survival of patients with melanoma (TCGA-SKCM project, n = 470). Patient data was categorized into samples within the top 10% of *CD36* gene expression (CD36-high, n = 47) and those within the bottom 10% of *CD36* gene expression (CD36-low, n = 47) (Fig. 1A). Analysis of these two cohorts showed a clear trend of decreased survival in patients who have high *CD36* gene expression, compared to those with low *CD36* expression, although this difference was not statistically significant (Fig. 1B).
Knockdown of CD36 by siRNA attenuates VM in melanoma cells

To determine whether CD36 expression contributes to VM in melanoma, in vitro VM assays were performed using two human melanoma cell lines, C32 and SK-MEL-28 without and with CD36 knockdown. Figure 2A and 2E confirm the VM capability of both C32 and SK-MEL-28 cell lines in vitro with Figs. 2B and 2F demonstrating the ability of three different CD36-targeting siRNA constructs to consistently knockdown CD36 protein expression with an efficacy of 70–90%. Having first confirmed that knockdown of CD36 did not compromise the viability of the cells (data not shown), we went on to examine the contribution of CD36 to VM formation. After 72 hours of CD36 knockdown, VM formation was significantly decreased in both the C32 (Fig. 2C and 2D) and SK-MEL-28 (Fig. 2G and 2H) cell lines, resulting in fragmented networks.

Exogenous TSP-1 does not inhibit VM capacity of melanoma cells

To investigate whether TSP-1, a known inhibitor of angiogenesis[32, 33] and a well-documented ligand for CD36, could also interfere with VM formation by CD36-expressing melanoma cells. In vitro, we performed VM assays with the C32 melanoma cells in the presence of increasing concentrations of TSP-1. Based on the literature of circulating TSP-1 in patient plasma ranging from 245 ng/ml, in healthy individuals, to 3650 ng/ml, in cancer patients[37], we included 0, 150 and 1500 ng/ml of TSP-1 into the VM assays. Figure 3A illustrates that the VM structures were not perturbed by the increasing concentrations of TSP-1. Further support for TSP-1 not being the relevant ligand for CD36 in VM comes from our inclusion of the anti-CD36 blocking antibody (FA6-152) that specifically blocks CD36 binding to TSP-1 and collagen[38–40]. Figure 3B shows that addition of this anti-CD36 blocking antibody did not inhibit VM formation, thus suggesting that neither TSP-1 nor collagen are involved in VM formation by melanoma cancer cells.

Importantly, to confirm our TSP-1 was indeed functional, we used the CD36 expressing human microvascular endothelial cells (HMVECs, Fig. 3C) in an angiogenesis assay [32, 33]. First, we confirmed that exposure of 1500 ng/ml of TSP-1 for up to 24 hours did not compromise cell viability (Fig. 3C), prior to addition of TSP-1 into the angiogenesis assay which showed a significant reduction in angiogenesis by the HMVECs when TSP-1 was present (Fig. 3D). This differential between EC angiogenesis and cancer cell VM has not been reported previously and goes some way to describing the important differences between these two contributing process of tumor vascularization.

CD36 receptor mediates melanoma cell adhesion to extracellular matrix components

To further investigate the role of CD36 on VM-competent melanoma cells, we performed inverse invasion assays wherein we tested the ability of C32 melanoma cells (without or with CD36) to crawl through an
extracellular matrix (Matrigel) towards a chemoattractant (10% FBS). Figure 4A shows that over 48 hours, the cells travelled between 50-150mm from the Transwell membrane with the majority travelling 100mm over that time. The loss of CD36 (via siRNA knockdown) did not impact on the cancer cells being able to invade up to 150mm. However, we observed that loss of CD36 significantly inhibited the number of C32 cells that migrated towards the FBS (Fig. 4A). This difference is best exemplified in Fig. 4B which illustrates the number of cancer cells at precisely 100μm from the Transwell membrane start point. With CD36 knockdown, there is a 50% reduction in cancer cells at this position. This data implies that CD36 facilitates an interaction between cancer cells and the extracellular matrix, and from our results above, this interaction is unlikely to involve TSP-1 or collagen.

**Melanoma cells utilize CD36 to bind to laminin substrata**

To further investigate how CD36 may be contributing to cancer cell invasion through the extracellular matrix components, adhesion assays were performed on Geltrex and a selection of components contained within Geltrex known to be bound by CD36, i.e. collagen I, collagen IV and laminin. Adhesion to fibronectin was also examined as a matrix component that does not engage CD36. Figure 5 shows that following knockdown of CD36, the C32 melanoma cells demonstrated reduced binding to Geltrex; adding further support to our findings of reduced VM and invasion. While no changes in cell adhesion were observed for C32 cells exposed to collagen I, collagen IV or fibronectin when CD36 was knocked down, reduced adhesion to laminin was observed for both CD36-targeting siRNA constructs (Fig. 5).

**Binding of melanoma cells to laminin is facilitated through integrin-α₃**

Given that Thorne et al previously demonstrated an association between CD36 and integrin-α₃β₁ on melanoma cells[41], and that integrin-α₃, but not CD36, binds laminin; we next examined whether blocking integrin-α₃ might inhibit the adhesion of VM-competent melanoma cells and laminin *in vitro*. First, flow cytometry confirmed the cell surface expression of integrin-α₃ on the C32 melanoma cells (Fig. 6A). Next, we observed that C32 cells bound to laminin and that this adhesion could be partly blocked via an anti-integrin-α₃ blocking antibody (Fig. 6B).

**Conclusions**

CD36, most widely known for its role as a scavenger receptor involved in the uptake of fatty acids, is gaining interest in the field of cancer research[29, 42, 43]. Expression of CD36 has been shown to correlate with poor prognosis (disease-free survival and overall survival) in luminal A breast cancer, lung squamous cell carcinoma, bladder cancer and melanoma[29, 44], with studies primarily focusing on the role of CD36 as a receptor for oxidized low density lipoprotein (oxLDL). Our own interrogation of the TCGA-SKCM database suggests that high expression of *CD36* correlates with poor clinical outcome for patients with melanoma (albeit not significantly) and corroborates the study by Nath and Chan[44]; thus lending further weight to investigating CD36 in melanoma.
Here we reveal an unexpected role for CD36 in VM formation by melanoma cancer cells. More specifically, using the *in vitro* angiogenesis assay with two human melanoma VM-competent cell lines[16], we observed that knockdown of CD36 by siRNA significantly prevented VM formation. To further examine the contribution of CD36 to VM formation, our invasion assays showed that in the absence of CD36 on melanoma cancer cells, their ability to migrate through an ECM was compromised, thus suggesting a direct interaction of CD36 with one or more components of the ECM. Interestingly, TSP-1, a known ligand of CD36 that inhibits angiogenesis by ECs[32, 45], was unable to inhibit VM formation by the cancer cells. Congruent with this, a CD36 blocking antibody (clone FA6-152) that specifically targets the epitopes for TSP-1 and collagen[38–40] also failed to prevent VM formation in our assays. Taken together, this data suggests that CD36-expressing VM-competent cancer cells may utilize CD36 differently to ECs for the formation of vascular structures; a process that is yet to be fully elucidated. Transient knockdown of CD36 in melanoma cells did not influence cell viability but did compromise the number of cells that migrated, again suggesting a role for CD36 in cell adhesion. This supports recent studies wherein CD36 proved important for the migration and invasion of breast cancer cells and cervical cancer cells *in vitro*[30, 46]. More specifically, these studies show that CD36 can promote the activation of the MAPK signaling pathway, upregulate protein expression of Bcl2 and cyclin D1 and engage with the TGF-b signaling for epithelial to mesenchymal transition (EMT) by cancer cells[30, 46].

To further elucidate the role for CD36 on cancer cells to engage with ECM components, adhesion assays were performed on collagen I, collagen IV, laminin and fibronectin, all of which are in high abundance in the ECM of tumors[47] and all are documented ligands for CD36[41]. Here we observed that loss of CD36 significantly reduced the ability of the melanoma cells to bind to the laminin substrata while retaining full binding capacity to collagen I, collagen IV and fibronectin. The retained binding to collagen is supported by our observations of the anti-CD36 monoclonal antibody (clone FA6-152[38–40]) failing to inhibit VM formation by the cancer cells. Our observation of CD36-knockdown melanoma cells exhibiting reduced adhesion to laminin concurs with a study by Ladanyi and colleagues who demonstrated that ovarian cancer cells utilize CD36 for adhesion to laminin[27]. A potential mechanism by which this interaction may occur is via a lateral association with integrins, specifically the laminin binding integrins α3β1 and α6β1[48, 49] both of which have been reported to associate with CD36 in human melanoma cells for enhanced migration on ECM components[41]. Here we reveal that like CD36, blocking integrin-α3 on melanoma cells inhibited the binding of melanoma cells to laminin *in vitro*. Taken together, this study leads us to hypothesize that CD36 expression by melanoma cells modulates the function of integrins to promote shape change and migration on ECM components, thereby facilitating the formation of VM structures (Fig. 7).

Increasing literature demonstrates that overexpression of CD36 in cell lines of cervical and oral squamous cell carcinoma significantly increases their metastatic potential *in vivo*[30] [29]. In accordance, CD36 neutralizing antibodies have been successfully used to combat metastasis in mouse models[29]. More specifically, repeated injections of the anti-CD36 antibody (clone FA6-152) significantly attenuated
the metastasis of oral squamous cell carcinoma without effect on the primary tumor[29]. Whether these anti-CD36 treated tumors contained fewer VM structures was not determined.

Our in-silico analysis of the TCGA database supports our hypothesis that high expression of CD36 correlates with poor outcome for patients with melanoma. Whether CD36 could serve as a useful biomarker for personalized medicine is not known, but with clinical trials targeting CD36 for patients with metabolic disease[42, 50], an opportunity to repurpose an anti-CD36 molecule remains of interest. Notably, caution surrounding CD36 as a target to treat cancer is unsurprising given that it is a fatty acid scavenger receptor with a wide range of ligands. Indeed, lipotoxicity was observed in tumor bearing mice treated with the CD36-neutralising antibody[29]. Clearly, while the refinement of CD36-targeting antibodies requires significant attention, there is increasing interest in CD36 as a potential prognostic for patients with colon, ovarian, breast, small cell lung carcinoma and urinary bladder cancer[29, 42, 43] and melanoma. This study adds to this interest by identifying a key role for CD36 in the lateral interactions with integrin-α3 to promote adhesion to the ECM (particularly laminin) to facilitate VM formation, an emerging process that contributes significantly to the progression of cancer (Fig. 7).

### Abbreviations

endothelial cell (EC); vasculogenic mimicry (VM); thrombospondin-1 (TSP-1); vascular endothelial (VE)-cadherin; ephrin receptor A2 (EphA2); platelet endothelial cellular adhesion molecule (PECAM-1); periodic acid-Schiff stain (PAS); microvascular ECs (MVECs); fetal bovine serum (FBS); small interfering RNAs (siRNAs); Human lung microvascular endothelial cells (HMVEC); bovine serum albumin (BSA); extracellular matrix (ECM); The Cancer Genome Atlas (TCGA); epithelial to mesenchymal transition (EMT)

### Declarations

**Ethics Approval and consent to participate:**

All cell lines were purchased from commercial sources or gifted as stated. No ethics approvals were required for this study.

**Consent for Publication:**

All authors have consented to the publication of this manuscript.

**Availability of data and materials:**

Not applicable.

**Competing interests:**
No listed authors have a conflict of interest that requires declaration.

**Funding:**

This project was supported by primary research grants to CSB from the NHMRC [GNT1022150] and the Royal Adelaide Hospital (RAH) Research Foundation. LE was supported by an RAH Research Foundation Florey Fellowship. CM was supported by an Australian Postgraduate Award.

**Authors contribution:**

Conceived and designed experiments: C.M, M.D., A.E.W., L.M.E and C.S.B. Performed experiments: C.M., M.D., D.K., M.P.C., and B.E. Analyzed data: C.M., M.D., M.P.C., and B.E. Wrote manuscript: C.M., L.M.E., A.E.W. and C.S.B. All authors have read and approved the manuscript

**Acknowledgements:**

The authors thank Samantha Escarbe for expert technical assistance and wish to acknowledge specimen donors and researchers within the TCGA Research Network.

**References**

1. El Hallani S, Boisselier B, Peglion F, Rousseau A, Colin C, Idbaih A, Marie Y, Mokhtari K, Thomas JL, Eichmann A et al: A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain : a journal of neurology 2010, 133(Pt 4):973-982.
2. Wang SY, Ke YQ, Lu GH, Song ZH, Yu L, Xiao S, Sun XL, Jiang XD, Yang ZL, Hu CC: Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma. Journal of neuro-oncology 2013, 112(3):339-345.
3. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM et al: Tumor vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468(7325):824-828.
4. Baeten CI, Hillen F, Pauwels P, de Bruine AP, Baeten CG: Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum 2009, 52(12):2028-2035.
5. Li W, Zong S, Shi Q, Li H, Xu J, Hou F: Hypoxia-induced vasculogenic mimicry formation in human colorectal cancer cells: Involvement of HIF-1a, Claudin-4, and E-cadherin and Vimentin. Scientific reports 2016, 6:37534.
6. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, Konishi F: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 2002, 99(6):821-828.
7. Liu TJ, Sun BC, Zhao XL, Zhao XM, Sun T, Gu Q, Yao Z, Dong XY, Zhao N, Liu N: CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer. Oncogene 2013, 32(5):544-553.

8. Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE, Hendrix MJ: Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001, 158(4):1279-1288.

9. Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJ: The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer biology & therapy 2002, 1(6):661-664.

10. Zhuo M, Yuan C, Han T, Hu H, Cui J, Jiao F, Wang L: JQ1 effectively inhibits vasculogenic mimicry of pancreatic ductal adenocarcinoma cells via the ERK1/2-MMP-2/9 signaling pathway both in vitro and in vivo. American journal of translational research 2019, 11(2):1030-1039.

11. Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Jr., Cohen MB, Lubaroff DM, Hendrix MJ: Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 2002, 50(3):189-201.

12. Hendrix MJ, Seftor EA, Hess AR, Seftor RE: Vasculogenic mimicry and tumor-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003, 3(6):411-421.

13. Delgado-Bellido D, Serrano-Saenz S, Fernandez-Cortes M, Oliver FJ: Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. Mol Cancer 2017, 16(1):65.

14. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, Trent JM, Meltzer PS, Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999, 155(3):739-752.

15. Folberg R, Hendrix MJ, Maniotis AJ: Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000, 156(2):361-381.

16. Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E et al: Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget 2016, 7(29):46492-46508.

17. Folberg R, Maniotis AJ: Vasculogenic mimicry. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2004, 112(7-8):508-525.

18. Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F, Iwanaga T, Konishi F, Terada M, Wakasugi H: Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer research 2002, 62(2):560-566.

19. Yang JP, Liao YD, Mai DM, Xie P, Qiang YY, Zheng LS, Wang MY, Mei Y, Meng DF, Xu L et al: Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: a meta-analysis. Angiogenesis 2016, 19(2):191-200.

20. Cao Z, Bao M, Miele L, Sarkar FH, Wang Z, Zhou Q: Tumor vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-analysis. Eur J Cancer 2013, 49(18):3914-3923.
21. Sun H, Zhang D, Yao Z, Lin X, Liu J, Gu Q, Dong X, Liu F, Wang Y, Yao N et al: Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry. Cancer biology & therapy 2017, 18(4):205-213.

22. Xu Y, Li Q, Li XY, Yang QY, Xu WW, Liu GL: Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res 2012, 31:16.

23. Hendrix MJ, Seftor EA, Seftor RE, Chao JT, Chien DS, Chu YW: Tumor cell vascular mimicry: Novel targeting opportunity in melanoma. Pharmacol Ther 2016, 159:83-92.

24. Fernandez-Cortes M, Delgado-Bellido D, Oliver FJ: Vasculogenic Mimicry: Become an Endothelial Cell "But Not So Much". Front Oncol 2019, 9:803.

25. Silverstein RL, Febbraio M: CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009, 2(72):re3.

26. Wang J, Li Y: CD36 tango in cancer: signaling pathways and functions. Theranostics 2019, 9(17):4893-4908.

27. Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A et al: Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene 2018, 37(17):2285-2301.

28. Hale JS, Otvos B, Sinyuk M, Alvarado AG, Hitomi M, Stoltz K, Wu Q, Flavahan W, Levison B, Johansen ML et al: Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression. Stem cells 2014, 32(7):1746-1758.

29. Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Attolini CS, Berenguer A, Prats N, Toll A, Hueto JA et al: Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 2017, 541(7635):41-45.

30. Deng M, Cai X, Long L, Xie L, Ma H, Zhou Y, Liu S, Zeng C: CD36 promotes the epithelial-mesenchymal transition and metastasis in cervical cancer by interacting with TGF-beta. Journal of translational medicine 2019, 17(1):352.

31. Mwaikambo BR, Yang C, Chemtob S, Hardy P: Hypoxia up-regulates CD36 expression and function via hypoxia-inducible factor-1- and phosphatidylinositol 3-kinase-dependent mechanisms. J Biol Chem 2009, 284(39):26695-26707.

32. Chu LY, Ramakrishnan DP, Silverstein RL: Thrombospondin-1 modulates VEGF signaling via CD36 by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells. Blood 2013, 122(10):1822-1832.

33. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD: Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999, 100(13):1423-1431.

34. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N: Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000, 6(1):41-48.
35. Tuszynski GP, Nicosia RF: The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays 1996, 18(1):71-76.

36. Hennigan RF, Hawker KL, Ozanne BW: Fos-transformation activates genes associated with invasion. Oncogene 1994, 9(12):3591-3600.

37. Tuszynski GP, Smith M, Rothman VL, Capuzzi DM, Joseph RR, Katz J, Besa EC, Treat J, Switalska HL: Thrombospondin levels in patients with malignancy. Thromb Haemost 1992, 67(6):607-611.

38. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP: CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997, 138(3):707-717.

39. Li Y, Qi X, Tong X, Wang S: Thrombospondin 1 activates the macrophage Toll-like receptor 4 pathway. Cell Mol Immunol 2013, 10(6):506-512.

40. Thelen T, Hao Y, Medeiros AI, Curtis JL, Serezani CH, Kobzik L, Harris LH, Aronoff DM: The class A scavenger receptor, macrophage receptor with collagenous structure, is the major phagocytic receptor for Clostridium sordellii expressed by human decidual macrophages. J Immunol 2010, 185(7):4328-4335.

41. Thorne RF, Marshall JF, Shafren DR, Gibson PG, Hart IR, Burns GF: The integrins alpha3beta1 and alpha6beta1 physically and functionally associate with CD36 in human melanoma cells. Requirement for the extracellular domain of CD36. J Biol Chem 2000, 275(45):35264-35275.

42. Enciu AM, Radu E, Popescu ID, Hinescu ME, Ceafalan LC: Targeting CD36 as Biomarker for Metastasis Prognostic: How Far from Translation into Clinical Practice? BioMed research international 2018, 2018:7801202.

43. Rachidi SM, Qin T, Sun S, Zheng WJ, Li Z: Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. PloS one 2013, 8(3):e57911.

44. Nath A, Chan C: Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. Scientific reports 2016, 6:18669.

45. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990, 87(17):6624-6628.

46. Liang Y, Han H, Liu L, Duan Y, Yang X, Ma C, Zhu Y, Han J, Li X, Chen Y: CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells. Oncogenesis 2018, 7(12):98.

47. Nallanthighal S, Heiserman JP, Cheon DJ: The Role of the Extracellular Matrix in Cancer Stemness. Front Cell Dev Biol 2019, 7:86.

48. Belkin AM, Stepp MA: Integrins as receptors for laminins. Microsc Res Tech 2000, 51(3):280-301.

49. Ramovs V, Te Molder L, Sonnenberg A: The opposing roles of laminin-binding integrins in cancer. Matrix biology : journal of the International Society for Matrix Biology 2017, 57-58:213-243.
Association of clinical outcome in melanoma patients with high CD36 expression (A) Patient data accessed from the TCGA-SKCM project (n=470) was categorized into the top and bottom 10% of CD36 gene expression (CD36-high (red) and CD36-low (black), respectively), ****p<0.0001, unpaired t-test. (B) From the data in A, a Kaplan-Meier analysis was conducted between the CD36-high and CD36-low populations (n=47 per group).
Figure 2

CD36 inhibition by siRNA attenuates VM by melanoma cells in vitro (A, E) Representative images of C32 and SK-Mel-28 human melanoma cells undergoing VM. For each cell line, the left image depicts VM with low magnification (scale bar = 500µm) and the right image is a zoomed in view of the same well using higher magnification (scale bar = 100µm). (B, F) Left panels, flow cytometric histograms of CD36 expression on C32 and SK-Mel-28 cells with isotype control (dotted line), CD36 (solid black line), and
siCD36 knockdown cells (solid red line). Right panels, bar graphs of flow data quantified from experimental repeats, siCD36 (constructs A-C) normalized to scrambled siRNA (si-SCR) controls. Data are expressed as mean ± SEM from n=3 experiments. ***p<0.001 vs si-SCR control, one-way ANOVA. (C, G) Representative images of C32 and SK-Mel-28 melanoma cells undergoing VM without or with siCD36 knockdown. For each cell line, the left image depicts VM with low magnification (scale bar = 500µm) and the right image is a zoomed in view of the same well using higher magnification (scale bar = 100µm). (D, H) Left panels, quantitation of VM formation by the cancer cells, normalized to si-SCR control within each experiment. Data are expressed as mean ± SEM from n=3 experiments. ***p<0.001 vs si-SCR control, one-way ANOVA. Right panels, cell viability without and with CD36 knockdown. Data are expressed as mean ± SEM from n=3 experiments.
Figure 3

Blocking CD36:TSP-1 interactions does not inhibit VM by melanoma cells (A) VM formation by C32 melanoma cells assessed following treatment with 150 and 1500 ng/ml TSP-1. Microscopy images are representative of VM with TSP-1 treatments (scale bar = 100µm). Right bar graph, number of VM normalized to untreated (UNT) controls. Data are mean ± SEM from n=3 experiments. (B) VM formation by C32 melanoma cells assessed following administration of anti-CD36 mAb prior to cell seeding for VM assay. Microscopy images are representative of VM (scale bar = 100µm). Right bar graph, number of VM normalized to untreated (UNT) controls. Data are mean ± SEM from n=3 experiments. (C) Left histogram, flow cytometric analysis of CD36 expression on HMVEC cells with isotype control (dotted line) and CD36 (solid line). Right bar graph, survival of HMVECs assessed without or with 1500 ng/ml TSP-1 for 6 hours. Data are mean ± SEM from n=3 experiments. (D) HMVEC angiogenesis without and with 1500 ng/ml TSP-1. Microscopy images are representative of EC angiogenesis (scale bar = 500µm). Right bar graph is number of EC branches per well normalized to untreated (UNT) controls. Data are mean ± SEM from n=3 experiments. *p<0.05, t-test.

Figure 4

CD36 facilitates the migration of melanoma cells (A) Left panel, quantitated data of the distance travelled by C32 melanoma cells towards 10% FBS with siCD36 (siRNA A or C) or siRNA control
CD36 aids selective adhesion by melanoma cells to components of the ECM Rose Bengal staining of C32 melanoma cells, without and with siCD36 knockdown (untreated (UNT), siRNA control (si-SCR), and CD36-targeting siRNA (siCD36 A and C)) following 90 minute exposure to plates coated with Geltrex,
Collagen I, Collagen IV, Laminin or Fibronectin. Data are mean ± SEM from n=3 experiments. * p<0.05, **p<0.01, one-way ANOVA.

**Figure 6**

Integrin-α3 supports melanoma cell adhesion to laminin (A) Flow cytometric analysis of integrin α3 expression on C32 melanoma cells with isotype control (dotted line) and integrin α3 (solid line). (B) Adhesion of C32 melanoma cells treated with an anti-integrin α3 antibody or isotype control onto tissue culture plates coated with 50μg/ml laminin. Microscopy images (left) illustrate the density of adherent cells on each well surface. Scale bar = 500μm. Bar graph (right), quantification of C32 melanoma cell adhesion to laminin (50μg/mL) as assessed following treatment with a blocking anti-integrin α3 antibody or isotype control. Results are normalized to control (ctl) wells and are mean ± SEM from n=3 experiments. *p<0.05, t-test.
Figure 7

Schematic concept of CD36 in VM formation and cancer progression. Solid tumor growth is underpinned by angiogenesis and VM. We hypothesize that CD36 expression by tumor ECs and the cancer cells themselves interacts with integrin-α3 to promote adhesion to the tumor ECM (particularly laminin) thus facilitating tumor vascularization (i.e. angiogenesis and VM) and cancer progression. Thrombospondin (TSP-1) is a ligand for CD36 and inhibits EC-lined angiogenesis. By contrast, VM by highly malignant melanoma cells is unperturbed when TSP-1 binds CD36. This schematic was conceptualized and crafted by CSB using Microsoft PowerPoint.